[Skip to Content]
[Skip to Content Landing]
Views 316
Citations 0
Research Letter
September 2016

Interpretability of the Modified Melasma Area and Severity Index (mMASI)

Author Affiliations
  • 1Department of Dermatology, St Vincent´s Hospital, Melbourne, Australia
  • 2Department of Dermatology, Royal Children´s Hospital, Melbourne, Australia
  • 3Department of Dermatology, University Hospital “José Eleuterio González,” Universidad Autónoma de Nuevo León, Monterrey, México
  • 4Department of Dermatology, Hospital Central “Dr Ignacio Morones Prieto,” Universidad Autónoma de San Luis Potosí, San Luis Potosí, México
  • 5Departments of Clinical Sciences–Biostatistics and Psychiatry, University of Texas Southwestern Medical Center, Dallas
  • 6Department of Dermatology, University of Texas Southwestern Medical Center, Dallas
JAMA Dermatol. 2016;152(9):1051-1052. doi:10.1001/jamadermatol.2016.1006

Melasma is a disorder of pigmentation commonly affecting women with darker skin types.1 Owing to the recalcitrant nature of melasma, more randomized controlled clinical trials of new treatment modalities are needed. These trials require precise categorization of disease severity to select appropriate patients for enrollment and determine response to treatment. The Melasma Area and Severity Index (MASI) is the most common outcome measure used for melasma studies, and was validated 20 years after it was first reported.2,3 This validation process eliminated homogeneity as a part of the MASI, resulting in the new modified MASI score (mMASI).3

First Page Preview View Large
First page PDF preview
First page PDF preview